遗传性血管的当前和新兴治疗方法
1Division of Allergy & Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Immunology and allergy clinics of North America
|June 27, 2024
概括
血管包括液体泄漏导致胀. 新的疗法针对布拉迪基宁介导的血管,显著改善遗传性血管 (HAE) 管理选择.
科学领域:
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管是由间歇性液体积聚而成的,导致非穴位.
- 条件被分类为巨细胞介导或布拉迪基宁介导.
- 从历史上看,布拉迪基宁介导的动脉瘤缺乏特定的治疗方法,与巨细胞介导的类型不同.
研究的目的:
- 审查目前对血管病理生理学的理解.
- 为了突出布拉迪基宁介导的血管治疗的最新进展.
- 讨论新疗法对遗传性血管 (HAE) 管理的影响.
主要方法:
- 对血管机制的文献综述.
- 对布拉迪基宁介导的血管治疗的最近临床研究的分析.
- 对HAE药物的监管批准进行审查.
主要成果:
- 血管腺被分为两种类型:质细胞介导和布拉迪基宁介导.
- 针对布拉迪基宁介导的血管已经出现了特定的治疗方法.
- 最近的药物批准扩大了HAE治疗选择.
结论:
- 布拉迪基宁介导的血管的治疗选择已经显著进步.
- 这些进展为遗传性血管提供了改进的治疗策略.
- 进一步的研究继续完善血管治疗模式.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700


